U.S. FDA approves Mirati's lung cancer drug https://ift.tt/uQwJsft

Adagrasib, an oral drug, is designed to target a mutated form of a gene known as KRAS that occurs in about 13 per cent of non-small cell lung cancers (NSCLC), the most common form of the disease, and less frequently in some other solid tumors. Mirati said the drug will be sold under the brand name Krazati at a price of $19,750 for a 200 milligram tablet/180 count bottle.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/VbApt0h